Chugai Pharmabody

Global Chugai News Release

Tuesday, 5 June 2018 5:00 AM

Chugai’s HEMLIBRA® Receives Priority Review Status from U.S. FDA for Hemophilia A without Inhibitors - Second Designation following Hemophilia A with inhibitors -

Tuesday, 29 May 2018 1:00 AM

Humanized Anti-Human IL-6 Receptor Monoclonal Antibody “ACTEMRA®,” Application for Approval of Additional Indication of Cytokine Release Syndrome Induced by Treatment with CAR-T Cell Therapy

Thursday, 24 May 2018 6:30 AM

Humanized Anti-Human IL-6 Receptor Monoclonal Antibody “ACTEMRA®,” Application for Approval of Additional Indication of Adult Onset Still's Disease